Showing 15 posts of 54 posts found.


Novartis’ Lucentis secures European approval for infants with rare eye disease

September 6, 2019
Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma

Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …

Roche’s eye drug beats Lucentis at Phase 2 in wet age-related macular degeneration

October 29, 2018
Research and Development, Sales and Marketing Genentech, Lucentis, Roche, eyecare, faricimab, pharma

Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration …

Roche granted further good news by FDA

October 11, 2016
Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america

Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …

Code of Practice

Bayer’s complaint over ‘misleading’ Novartis eye drug claims upheld

August 14, 2015
Medical Communications Bayer, Eylea, Lucentis, Novartis, PMCPA, code of conduct

The industry’s code of conduct regulator has ruled in favour of Bayer in a dispute claims made by Novartis when …

Lucentis image

Novartis accused of Lucentis ‘campaign’ against Avastin

April 2, 2015
Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD

Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …

Bayer image

Bayer and Regeneron eye drug gains another indication

March 26, 2015
Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept

Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …

Avastin image

Doctors appeal to prescribe Avastin off-label

February 25, 2015
Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD

NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …

Roche image

FDA clears Roche eye drug

February 9, 2015
Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab

The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …

France ‘to approve’ Avastin use

July 3, 2014
Sales and Marketing AMD, France, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The French government is planning to allow Roche’s cancer drug Avastin to be prescribed off-label to treat wet age-related macular …

Avastin image

EU looks at eye drug allegations

May 8, 2014
Sales and Marketing EU, Lucentis, Novartis, Roche, avastin, offlabel

European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …


Roche/Novartis offices raided over anti-competitive activities

April 11, 2014
Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD

French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …

Lucentis image

NICE gives Lucentis more scope

November 27, 2013
Sales and Marketing Lucentis, NICE, Novartis, cnv

An undisclosed price cut from Novartis has been enough to swing NICE towards using the manufacturer’s Lucentis in a fourth …

Lucentis image

NICE ‘yes’ to Lucentis – with price cut

October 25, 2013
Sales and Marketing Dillon, Lucentis, NICE, Novartis

A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …

set your sights image

Novartis launches Facebook ‘retina app’

October 15, 2013
Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights

Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …

Latest content